{
    "clinical_study": {
        "@rank": "154692", 
        "arm_group": {
            "arm_group_label": "Kinerase", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the K.I.S.S. study is to evaluate the efficacy of Kinerase\u00ae Cream (Kinetin\n      0.1%) in Thai patients, on the basis of the severity and clinical signs of facial\n      photodamage."
        }, 
        "brief_title": "Efficacy and Safety Study of Kinerase\u00ae for Treatment of Cutaneous Facial Photodamage", 
        "condition": [
            "Skin Roughness", 
            "Mottling", 
            "Blotchiness", 
            "Pigmentation", 
            "Fine Wrinkles"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male and female subjects older than 35 years of age and less than 65 years of age.\n\n          2. Subjects with mild, moderate or severe facial photodamage as assessed by a 10-point\n             scale.\n\n          3. Subjects willing to sign an informed consent and adhere to all protocol requirements.\n\n        Exclusion Criteria:\n\n          1. Male and female subjects with suspected porphyria, systemic or cutaneous\n             erythematosus lupus, or any other photosensitizing disorder or drug-induced\n             photosensitization.\n\n          2. Subjects with chronic or recurring skin disease or disorder.\n\n          3. Subjects with any active infectious skin disorder (Herpes simplex, molluscum\n             contagiosum, and facial warts).\n\n          4. Subjects with skin cancer of the facial tissues.\n\n          5. Subjects who have received any laser/ intense pulsed light (IPL) / chemical peel in\n             the 2 months preceding the screening visit.\n\n          6. Subjects with a history of topical and/or oral isotretinoin use, 6 months prior to\n             the screening visit.\n\n          7. Subjects who have been on topical Retin-A or Renova in the 2 months prior to the\n             screening visit.\n\n          8. Subjects who have used topical alpha-hydroxy acid skin care products in the month\n             preceding the screening visit.\n\n          9. Subjects currently on any anti-aging products and who wish to continue use of their\n             products.\n\n         10. Subjects requiring concurrent treatment that would interfere with the study\n             assessments.\n\n         11. Pregnant or lactating female subjects."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885091", 
            "org_study_id": "K.I.S.S"
        }, 
        "intervention": {
            "arm_group_label": "Kinerase", 
            "intervention_name": "Kinerase", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Kinetin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10500"
                }, 
                "name": "I-Sky Center Chidlom branch"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "1", 
        "official_title": "Kinerase\u00ae Interactive Skin-care Study: A Multicentre, Phase IV, Single-arm, Open-label Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Facial Photodamage", 
        "overall_official": {
            "affiliation": "iSKY Innovative Skin & Laser Surgery Center", 
            "last_name": "Rungsima Wanitphakdeedecha, MD, MA, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Ministry of Public Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "To assess the physician's evaluation and patient's self-evaluation at 12 weeks.", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "To assess the physician's evaluation and patient's self-evaluation at 4 weeks.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "To assess the physician's evaluation and patient's self-evaluation at 8 weeks.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885091"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Menarini (Thailand) Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Menarini (Thailand) Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}